Skip to main content

Table 2 The panel of cytotoxic drugs classified according to their therapeutic targets, primary effector pathways, or signaling pathway; and the sensitivity for each malignant cell lines

From: Optimization of combination chemotherapy based on the calculation of network entropy for protein-protein interactions in breast cancer cell lines

Drugs group NuclSynta Metabb DNAc Variousd Average
Targets Ie IIf IIIg IVh  
Li      
MCF-7 4.72 NA 5.07 6.10 5.30
T-47D 3.01 4.46 5.19 5.39 4.51
ZR-75-1 5.16 4.16 5.99 5.65 5.24
BT-474 3.12 3.98 4.76 5.89 4.44
Correl.j 0.500j 0.433 0.961 −0.623 0.401
TNk      
BT-20 3.48 4.69 4.93 5.50 4.65
MDA-MB-231 3.44 4.13 5.71 5.40 4.67
MDA-MB-468 4.31 4.03 5.59 6.04 4.99
Correl. −0.845 0.926 −0.785 −0.783 −0.891
Tot. correl.l 0.197 0.633 0.486 −0.683 0.126
  1. aNuclSynt: DNA synthesis
  2. bMetab: antimetabolites
  3. cDNA: alter DNA structure
  4. dVarious: diverse spectrum of biological activities
  5. eI: TYMS, DNA, RNA, DHFR, GART
  6. fII: FDPS
  7. gIII: DNA cross-linker, TOP1, TOP2A, TOP2BA, TOP2AB, pyrimidine anti-metabolite
  8. hIV: PSMD2, PSMB1, PSMB5, PSMB2, PSMD1, IKBKB, SRC, MDM2, FLT3, NTRK1
  9. iLuminal: Luminal A and B
  10. jCorrel: Correlation of drug 50 with entropy per node (see Table 1)
  11. kTN: Triple-negative
  12. lTot. correl: correlation for L and TN together